Great Ormond Street Hospital for Children NHS Foundation Trust

gosh.nhs.uk

Total trials

82

Active

13

Phase 3

2

Total enrollment

18,800

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 3 of 3 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Lentiviral vector transduced CD34+ cells2
Cryopreserved BE CAR33 T Cells1
Indocyanine Green1

Next readouts

  • 2026-06-01
  • 2026-08
  • 2028-08
  • 2029-04-01

Top conditions

  • Epilepsy3
  • Cystic Fibrosis3
  • Dilated Cardiomyopathy2
  • Spinal Muscular Atrophy2
  • Child2
  • Critical Illness2
  • Children, Only2
  • Haemodiafiltration2

Frequently asked questions about Great Ormond Street Hospital for Children NHS Foundation Trust

How many clinical trials does Great Ormond Street Hospital for Children NHS Foundation Trust have on ClinicalTrials.gov?
Great Ormond Street Hospital for Children NHS Foundation Trust is listed as the lead sponsor on 82 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of Great Ormond Street Hospital for Children NHS Foundation Trust's trials are in Phase 3?
2 of Great Ormond Street Hospital for Children NHS Foundation Trust's trials are in Phase 3, spread across 3 active drug programs.
What therapeutic areas does Great Ormond Street Hospital for Children NHS Foundation Trust focus on?
Great Ormond Street Hospital for Children NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Epilepsy, Cystic Fibrosis, Dilated Cardiomyopathy, Spinal Muscular Atrophy, Child.
When are Great Ormond Street Hospital for Children NHS Foundation Trust's next clinical trial readouts?
Great Ormond Street Hospital for Children NHS Foundation Trust has 4 upcoming primary-completion readouts tracked here; the soonest is “Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation”, expected around 2026-06-01.